Drug Discovery and Clinic is a private biotech company focused on developing novel therapies to address infectious disease and cancer. The company’s lead drug candidate, DDC#1, is a dihydroorotate dehydrogenase (DHODH) inhibitor with oral bioavailability and high potency. DDC is evaluating DDC#1 in preclinical as a potential treatment for Acute myeloid leukemia. The company is also assessing DDC#1 as a potential treatment for COVID-19